strategy, investment, partnering and deal ... 2019 brochure.pdf17:30 - general macro challenge...

October 7-8, 2019 Convene Convention CenterBoston, USA

2nd Annual Conference

www.lsxleaders.com/usa #lsxusa @lsxleaders Created by

STRAT EGY, I NVESTMENT, PARTNERING AND D EAL M AK I NG FOR L IFE SC IENCE

EX ECUTIVE LEADERS

http://www.lsxleaders.com/lsx-usa-congress

LSX World Congress USAWhat is it and who is it for?

LSX World Congress USA October 7-8, 2019

www.lsxleaders.com/usa

The 2nd annual LSX World Congress USA is a high-caliber, senior executive, two-dayconference and partnering event providing the education, strategies, solutions andcontacts that life science companies need to enable more effective investment,planning and strategic growth within their businesses. The US edition of the WorldCongress follows on from five previous highly successful congresses following theunique style and format of LSX in London.

http://www.lsxleaders.com/usa

Why Attend?



Understand the long term trends affecting the industry from industry-leading investment funds, global headsof pharma BD and CEOs of some of the world’s most exciting healthcare businesses

Hear war stories, advice and key success factors from CEOs who have taken their company through major milestones andwho are internationalizing thebusinesses

Participate in one of our unique, curated, invitation only Chatham House Rule Forums for Investors, Early Stage and Growth Stage Private companies

Network with 200+ life science CxOs, international investors and key partners, convening to address key executive issues facing companies in the sector

Sign-up to one or more of four workshops offering practical advice, guidance and outcome orientated content for companies positioningthemselves for licensing deals, clinical progress and value based regulatory strategies

Connect with Purpose to our community - the life science executives of LSX



Speakers


Kenneth BarrSVP, Head of Discovery Services, Syngene

Jeff Behrens President & CEO, Siamab Therapeutics

Alan Crane Entrepreneur Partner, Polaris Partners

Laura Benjamin Founder & CEO, Oncologie

David De Graff CEO, Comet Therapeutics

Andrew ElBardissi Principal, Deerfield Management

Peter Dudek Partner, MRL Ventures Fund

Constantine Chinoporos CBO, Boston Pharmaceuticals

Nicole Bocskocsky VP of Clinical Operations, Parsley Health

Mark R. Fitzgerald Partner, Wilson Sonsini Goodrich & Rosati

Neal Farber CEO, NeuroHealing Pharmaceuticals

Meredith FisherPartner, Partners Healthcare

Melissa Fensterstock Co-Founder and CEO, Lansdowne Labs

Todd Foley Managing Partner, MPM Capital

Adam Houghton VP & Head, AbbVie Ventures

Nouhad HusseiniVP, Head of BD, Regeneron Pharmaceuticals

Patrick JordanCEO, Mycovia

Alex BargarVice President of Clinical Services, Simple Health

Sharon Choe SVP, IR & Business Development, LaVoie Health Science

Kelly GoldVP, Corporate Development, CAMP4 Therapeutics

Alexandra Glücksmann CEO, Cedilla Therapeutics

John Glasspool CEO, Anthos Therapeutics

Farah Gerdes Partner, Technology Transactions, Wilson Sonsini Goodrich & Rosati

Darin De Carlo Sr Principal & Segment Lead, IQVIA

Ed Kaye CEO, Stoke Therapeutics

Thomas Goodin Senior Director, Clinical Development, Sunovion Pharmaceuticals

Dan Grau CEO, Sojournix

Ariane Horn Partner, Arnold and Porter

Jeffrey Handwerker Partner, Arnold and Porter

Jeff Berkowitz CEO & Director, Real Endpoints



Speakers


Veronique RiethuisenSVP, Global Head of BD & Alliance Management, Ipsen

Aaron Nelson Principal, Novartis

Priyanka RohatgiManaging Director, Head, Ipsen Ventures

Adam Rosenberg President & CEO, Rodin Therapeutics

Satish Sanan Chairman and CEO, Inspirata, Inc.

Aradhana Sarin Chief Strategy & Business Officer, Alexion Pharmaceuticals

Ricky Sun Partner, Life Sciences, Bain Capital

Marshall Smith Head of Global Healthcare, Goldman Sachs

Laurie Smaldone Alsup MD, CSO, NDA Group

Jay Sales Director, Advanced Technology, VSP Global

Ori Solomon Partner, Corporate Department & Co-chair, Emerging Companies & VC, Morrison Foerster

Derek Stoldt Co-head, M&A & Life Sciences Transactions Practice, Arnold & Porter

Nigel Sheail Global Head of M&A, Business Development & Licensing, Novartis

Christopher Stepanian CEO, WindGap Medical

Laura Tadvalkar Principal, MP Healthcare Venture Management

Ted Tanner Jr. CTO and Chief Architect, Watson Health, IBM

Ailis Tweed-KentCEO, Cocoon Biotech

Rogerio VivaldiCEO, Sigilon Therapeutics

Carolyn Witte Co-Founder and CEO, Tia

Paul Spreen Executive Vice President, IQVIA

Philippe Lopes-Fernandes SVP, Global Head of BD & Alliance Management, Merck KGaA

Donna LaVoie President & CEO,LaVoie Health Science

Allan Morgan Senior Director, IQVIA

James Siestra CBO & Co-Founder, Totient, Inc.

Joshua ResnickManaging Partner, RA Capital Management

Anjali Kumar External Innovation Search and Evaluation, Eastern United States, Johnson & Johnson Innovation, Boston

Anne Whitaker CEO & Director, Dance Biopharm

Shakti Narayan CEO, Accent Therapeutics


Agenda at a glance

October 7-8, 2019LSX World Congress USA


Forum - 7th October

Conference - 8th October 9:00

Keynote Plenary

18:00CEO Drinks & Dinner

Start-up / Early Stage CEO Forum Growth / Late Growth Stage CEO Forum13:00

Clinical Strategies Workshop

Main Plenary

Pharma BDForum

Licensing & Collaboration Workshop

Value Based Pricing & Contracting Workshop

Main Plenary

Pharma BDForum

Keynote Plenary

1-2-1 Meetings

1-2-1 Meetings

1-2-1 Meetings

1-2-1 Meetings

10:40

Registration and Networking Lunch12:00

Networking Lunch12:50

13:50

16:00

Close of Conference17:20

Networking Break15:00/15

Start-up / Early Stage CEO Forum Growth / Late Growth Stage CEO Forum 15:30/45

Networking Break

11:10

Networking Break15:30


Forum Day - October 7th



Session Moderator: Paul Sagan, Assistant VP, Investor Relations and Corporate Communications, LaVoie Health Science

13:00 - Intro from moderator, hosts and 60sec elevator pitch from all executives in the room

13:15 - Case study: non-dilutive funding to advance R&D Jeff Behrens, President & CEO, Siamab Therapeutics

13:30 - Q&A

13:45 - Case study: anatomy of a first round financing Mark R. Fitzgerald, Partner, Wilson Sonsini Goodrich & Rosati + James Siestra, Co-founder, Totient Inc. 14:30 - Q&A

14:45 - Case Study: International Investment and Company Building: Oncologie A + B with Asian investment partners Laura Benjamin, Founder & CEO, Oncologie

15:00 - Q&A

15:15 - Afternoon Break

Session Moderator: Sharon Choe, SVP, IR and Business Development, LaVoie Health Science

15:45 - Presentation: how to create your life science company presentation in just 15 slides Donna LaVoie, President & CEO, LaVoie Health Science

16:15 - Q&A

16:30 - Case study: following an asset centric approach to growing your business Arthur Hiller, CEO, Antyllus Therapeutics, Inc.

16:45 - Q&A

17:00 - Case study: early-stage partnerships to launch and grow your business Christopher Stepanian, CEO, WindGap Medical

17:15 - Q&A

17:30 - General macro challenge discussion not restricted to valuation, alternative growth strategies and research partnershipsExecutives will have the opportunity to highlight areas of interest prior to the afternoon break to aggregate themes for this 30mins session.

18:00 - Networking Drinks followed by CEO Dinner Delegates will be directed to the venue at 18:00

A unique, powerful and valuable space for the candid sharing of experience between 20-30 of the sector’s pre-series A life science executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants.

Hosted by

12:00Registration and Networking Lunch

13:00

Choose from 2x CEO Forums for private early stage and private growth / late growth stage executives to uncover KSFs relating to your company stage.


Forum Day - October 7th



Session Moderator: John Hodgson, Director, PersComm Ltd.

13:00 - Intro from moderator, hosts and 60sec elevator pitch from all executives in the room

13:15 - Case study: challenges in securing later stage investment Dan Grau, CEO, Sojournix

13:30 - Q&A

13:45 - Case study: legal and business challenges in securing late stage financing Ori Solomon, Partner, Corporate Department and Co-chair, Emerging Companies and Venture Capital, Morrison Foerster

14:00 - Q&A

14:15 - Case study: Considerations for a commercialization model: how to optimize value to patients and stakeholders Allan Morgan, Senior Director, IQVIA & Anne Whitaker, CEO and Director, Dance Biopharm

14:45 - Q&A

15:00 - Afternoon Break

15:30 - Case study: Taking your products through the clinic / clinical / R&D strategies Adam Rosenberg, CEO, Rodin Therapeutics

15:45 - Q&A

16:00 - Case study: finding new directions for success after clinical failures Neal Farber, CEO, NeuroHealing Pharmaceuticals

16:15 - Q&A 16:30 - Case study: M&A as a strategic multiplier Satish Sanan, Chairman and CEO, Inspirata, Inc.

16:45 - Q&A 17:00 - Case study: preparing commercial go-to-market, strategies and activities John Glasspool, CEO, Anthos Therapeutics

17:15 - Q&A

17:30 - Plus General macro challenge discussion not restricted to valuations and dilutions, research partnerships, market access, pricing and exit dynamics Executives will have the opportunity to highlight areas of interest prior to the afternoon break to aggregate themes for this 30mins session.

18:00 - Networking Drinks followed by CEO Dinner Delegates will be directed to the venue at 18:00

A unique, powerful and valuable space for the candid sharing of experience between 20-30 of the sector’s post-series A life science executives. A pre-registration only, exclusive hollow square forum where all participants are active discussants.

Hosted by

13:00


Conference Day - October 8thOctober 7-8, 2019LSX World Congress USA


10:40Networking Break

10:00PHARMA PANEL: STRATEGIC SHIFTS IN ADDRESSING PIPELINE DRIFT; PHARMA M&A AND PARTNERING IN 2020

Not withstanding the legacy factors continuing to influence strong deal flow, how is Pharma responding to the emerging encroachment of tech giants into their territories? Does this present co-operation opportunities or unwelcome competition and how will this impact external M&A, partnering and consolidation strategies? Moderator: Jerry Lee, Managing Director, Goldman Sachs Veronique Riethuisen, SVP, Global Head of Business Development & Alliance Management, IpsenPhilippe Lopes-Fernandes, SVP, Global Head of BD & Alliance Management, Merck KGaA Nigel Sheail, Global Head of Mergers & Acquisitions and Business Development & Licensing, Novartis Aradhana Sarin, Chief Strategy & Business Officer, Alexion Pharmaceuticals

CORPORATE INVESTOR PANEL: NOTHING VENTURED, NOTHINGGAINED; BACKING BIGGER ROUNDS AND MAKING BIGGER BETS

With the size of the average investment rounds getting bigger across the entire venture industry how are CVCs aligning with this trend? What can we expect to see from CVCs in terms of leading investment rounds and how is the macro environment affecting the approaches CVCs are taking. Plus, executives share some insights into their current investment preferences.

Moderator: Derek Stoldt, Co-Head, M&A and Life Sciences Transactions Practice, Arnold & Porter Peter Dudek, Partner, MRL Ventures FundPriyanka Rohatgi, Managing Director, Head, Ipsen VenturesAaron Nelson, Principal, Novartis Venture FundAdam Houghton, Vice President and Head, AbbVie Ventures Laura Tadvalkar, Principal, MP Healthcare Venture Management (MPH)

11:10

EXECUTIVE PANEL: RAISING THE BAR; MAKING THE ‘SERIES’ A GRADE

In an industry becoming increasingly defined by weighty Series A’s, executives who have been instrumental in achieving incredible early-stage venture raises share their success stories and war stories in equal measure. Plus, share what we can expect to see from their companies as they continue to deploy their capital. Moderator: Ori Solomon, Partner, Corporate Department and Co-chair, Emerging Companies and Venture Capital, Morrison FoersterDavid De Graaf, CEO, Comet TherapeuticsMichael Pavia, CEO, Tuned Therapeutics Andrew ElBardissi, Principal, Deerfield ManagementAlexandra Glücksmann, CEO, Cedilla Therapeutics

11:50

8:00Registration and Breakfast

9:00KEYNOTE PRESENTATION: CAPITAL MARKETS OUTLOOK

Marshall Smith, Head of Global Healthcare, Goldman Sachs

What are the factors currently fuelling VC and public markets, how are these affecting the entrepreneurial scene and more well established firms and how do executives see these impacting appetite and strategies for investing and company building? Plus, with prominent reloads, what areas are grabbing investor’s attention? Moderator: Paul Spreen, EVP and Chief Customer Officer, IQVIATodd Foley, Managing Partner, MPM CapitalRicky Sun, Partner, Life Sciences, Bain CapitalMeredith Fisher, Partner, Partners HealthcareAlan Crane, Entrepreneur Partner, Polaris PartnersJoshua Resnick, Managing Partner, RA Capital Management

9:20INVESTOR PANEL: MACRO TRENDS, MARKET CORRECTIONS ANDUNMET MEDICAL NEED

12:30PRESENTATION: LEVERAGING STRATEGIC PARTNERSHIPS TO ACCELERATE THE PROGRESS OF YOUR MOLECULE(S)

Kenneth Barr, SVP, Head of Discovery Services, Syngene


Conference Day - October 8thOctober 7-8, 2019LSX World Congress USA


13:50EXECUTIVE PANEL: DE-RISKING THE REGULATORY APPROVAL PATH - HOW TO OPTIMIZE YOUR INVESTMENT DOLLARS

15:10

Networking Break

The path to global product approval is notorious for hurdles from every angle; from technical/scientific risk to regulatory and market access risk. The hurdles are even more evident when there is limited or no precedent for the indication being sought that could impact time, cost and approvability. Executives explore the best ways to minimize these risks and probe cases that address these issues dur-ing development, sharing de-risking strategies for keep innovative programs on track.

Moderator: Laurie Smaldone Alsup, MD, CSO, NDA GroupEd Kaye, CEO, Stoke TherapeuticsAilis Tweed-Kent, CEO, Cocoon Biotech John Glasspool, CEO, Anthos TherapeuticsChristine Swenson, Head, Regulatory Affairs, Moderna Therapeutics

14:50KEYNOTE CHAT: THE RATIONALE OF AI IN HEALTHCARE? IT’S HUMAN NATURE Ted Tanner Jr., CTO and Chief Architect, Watson Health, IBM Jay Sales, Director, Advanced Technology, VSP Global

PRESENTATION: COMMERCIALIZATION: ALTERNATIVE TO A TRADITIONAL EXIT PLAN

EXECUTIVE PANEL: MOVERS, SHAKERS AND THERAPEUTIC DEAL MAKERS

With lofty biotech valuations and rising competition in key therapeutic fields, executives who have positioned their companies as attractive for deal making opportunities share their experiences, KSFs and fundamentals when engaging big pharm. Plus executives share what we can expect to see from their respective companies in the year ahead. Moderator: Farah Gerdes, Partner, Technology Transactions, Wilson Sonsini Goodrich & RosatiRogerio Vivaldi, CEO, Sigilon Therapeutics Kelly Gold, Vice President, Corporate Development, CAMP4 TherapeuticsNouhad Husseini, Vice President, Head of Business Development, Regeneron PharmaceuticalsConstantine Chinoporos, CBO, Boston Pharmaceuticals

16:00

CLOSING PANEL: KNOCKING ON THE DOOR; THE BOOMINGDIRECT-TO-CONSUMER (D2C) HEALTHCARE MODEL

With tech players increasingly encroaching in healthcare, forcing companies — as well as startups — to think of different ways to reach patients, and investors wagering that consumers will be increasingly willing to shop for healthcare the same way they buy more traditional products online, what can we expect from the D2C model?

Moderator: John Hodgson, Director, PersComm Ltd. Alex Bargar, VP Clinical Services, Simple Health Melissa Fensterstock, Co-Founder and CEO, Lansdowne LabsCarolyn Witte, Co-Founder and CEO, TiaNicole Bocskocsky, VP of Clinical Operations, Parsley Health

16:40

15:30

17:20Close of Congress

12:50Networking Lunch

The importance of a robust development and commercialization strategy has never been more evident. This presentation will outline the considerations needed as your drug progresses through the developmental phases towards the market and share advice on how to minimize the risk that your company’s therapy will end up a commercial failure.

Darin DeCarlo, Senior Principal and Segment Lead, IQVIA

14:30PARTNERING WITH J&J: THE WHY, HOW AND WHAT Anjali Kumar, External Innovation Search and Evaluation, Eastern United States, Johnson & Johnson Innovation, Boston


Conference Day - October 8thSatellite Forums


Pharma BD Forum is a high profile forum designed primarily for global and regional BD heads from the larger and mid cap ( >$1bn) Pharma and Biotech companies, and key influential partners and stakeholders in the sector.

The forum will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole. This is an invite-only forum and not open to general attendees.

Location: South Boardroom

The clinical strategies workshop is a 1.5hr intimate, interactive forum in which a leading CRO partner hosts an intimate group of CxOs who are transitioning into clinical development and interested in exploring business models and approaches to partnerships in clinical trials. Panel: Clinical Strategies Workshop: Capturing the attention of investors Michael Kardas, Vice President, Strategic Drug Development, IQVIA Patrick Jordan, CEO, Mycovia Thomas Goodin, Senior Director, Clinical Development, Sunovion Pharmaceuticals Inc. This is a unique opportunity for candid sharing of experiences with an intimate group of biopharma executives transitioning into clinical development. The session includes:

• Discussion of the key elements of long term strategic planning that enables you to articulate a compelling value to investors.

• Panel discussion with biopharma executives• Q&A session

Location: The Hub West

11:00



The Licensing & Collaboration Workshop is a 1.5hr intimate, interactive forum in which CEOs and CBOs navigate the how, what, where and when of a successful licensing deal / strategic collaboration.

Delivering strategy, tactics, mechanics and ideas. Licensing & Collaboration Deals: Trends and DriversFarah Gerdes, Partner, Technology Transactions, Wilson Sonsini Goodrich & Rosati

• Why collaborate?• Market Trends & Drivers• Traditional drivers• Early stage vs. Late Stage• Deal elements that drive value• Beyond the NCE – subject matter/technology

being licensed• The changing the face of collaborations:• Technology• Big Data• Open innovation

Case study of a successful licensing dealShakti Narayan, CEO, Accent Therapeutics Key Considerations in Licensing & Collaboration Deals The Collaboration Lifecycle, Key terms, Scope, Governance, Financials, IP, Exit, Impact of trends on deal terms and Future-proofing the deal

Location: The Library

1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots.

8 hours of enabled partnering outside of the informal networking during breaks will be scheduled from approx. 8.30am - 5pm on the 8th October.

Location: The Hub East


Conference Day - October 8thSatellite Forums cont.



Pharma BD Forum is a high profile forum designed primarily for global and regional BD heads from the larger and mid cap ( >$1bn) Pharma and Biotech companies, and key influential partners and stakeholders in the sector.

The forum will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole. This is an invite-only forum and not open to general attendees.

Location: South Boardroom

1-2-1 partnering will take place in a dedicated room with private meeting tables and 30min allocated slots.

8 hours of enabled partnering outside of the informal networking during breaks will be scheduled from approx. 8.30am - 5pm on the 8th October.

Location: The Hub East

13:50

15:30Networking Break


1-2-1 PARTNERING

The value-based pricing and contracting workshop is a 1.5hr intimate, interactive forum for CEOs who are implementing value-based strategies in order to meet the needs of the patients, payers and regulators. Workshop Leaders Jeffrey Handwerker, Partner, Arnold & Porter Ariane Horn, Partner, Arnold & Porter 13.50 Overview of Value-Based Strategies

• What is a Value-Based Arrangement?• Why Value-Based Arrangements Are of Interest to Manufacturers, Payers, State• Agencies and other Stakeholders?• Types of Agreements• Key Legal Considerations

• Anti-Kickback Statute• Drug Price Reporting• Off-Label Promotion• Privacy• Government Transparency

14.50 Case Studies / Panel Discussion

• Payer rebates based on adherence measures• Payer rebates based on failure to achieve pre-specified efficacy measures• Payer rebates based on total costs of care for patients on one drug versus patients on different drugs• Hospital delayed payment pending achievement of pre-specified efficacy measures

Location: The Hub West

14.30 Business Perspectives on Value-Based Strategies

• Jeff Berkowitz, CEO and Director, Real Endpoints




Our PartnersPlatinum Partners

Gold Partners

Supporting Partners

Media Partners

Silver Partner


Confirmed 2019 Attendees



Managing Director & Founder, 37celsiusHead of East Coast Business Development & Acquisitions, AbbvieVP & Head, AbbVie VenturesVenture Partner, AbingworthOperating Partner, AccelmedCEO, Accent TherapeuticsChairman & CEO, ACS Global (American CryoStem Corporation)Head of Business Development for USA, AdlaiNortye USA IncManaging Partner, AlacritaSenior Consultant, AlacritaPresident & Founder, Alertgy IncCorporate Strategy & Business Development, Alexion PharmaceuticalsSVP, Head of Business Development & Strategy, Alexion Pharmaceuticals, Inc.Sr. VP, Allied MindsCOO, American CryosystemCEO, AMRA MedicalVP of Strategic Alliances & Licensing, Amryt PharmaCEO, Anthos TherapeuticsCEO, Antidote.meCEO, Antyllus TherapeuticsPresident & CEO, Aqua Medical, Inc.Partner, Arnold & PorterPartner, Arnold & PorterPartner, Arnold & PorterPartner, Arnold & PorterPartner, Arnold & PorterVP, Corporate Strategy & Development, AstraZenecaCEO & Co-Founder, Astrocyte Pharmaceuticals Inc.Managing Director, AUGCChief Executive Officer and Managing partner, Back Bay Life Science AdvisorsPrincipal, Bain CapitalHead of Global Business Development, Licensing and Specialty Medicine, Bayer Healthcare PharmaceuticalsAssociate Editor, BioCentury PublicationsFounding Partner, BOHE Angel FundCBO, Boston PharmaceuticalsSenior Director, Asset Acquisition, Bridge BioAssociate, Broadview VenturesAssociate, Broadview VenturesPrincipal, Broadview VenturesPresident & CEO, Caladrius BiosciencesVP, Investor Relations & Corporate Communications, Caladrius BiosciencesPresident, Cambridge BioPartnersCEO, CAMP4 TherapeuticsVP Corporate Development, CAMP4 Therapeutics

Associate Director Business Development, CAMP4 TherapeuticsPrincipal, Capital Family OfficeCEO & Co-Founder, Cardiomo CareCTO, Cardiomo CareHead of Practice - Pharmaceutical & Biotech EMEA, Carmichael Fisher Executive SearchPresident & CEO, Cedilla TherapeuticsChief Executive Officer, Cereno Scientific ABChairman of the Board & CEO, ChemioCareLife Tech Industry Manager, City of BostonDirector of Economic Development, City of CambridgeSenior Economic Development Manager, City of CambridgeCo-Founder & Managing Director, Co-D Therapeutics, Inc. Executive Chairman, Co-D Therapeutics, Inc. Founder & CEO, Cocoon BiotechCBO, Codiak BiosciencesCEO, Comet TherapeuticsDirector of Business Development, Corbus Pharmaceuticals IncManaging Director Healthcare Investments, Cowen Healthcare InvestmentsPartner, Cure VenturesProject Leader: Precision Medicine Initiative, CVBCEO, Dance BiopharmPrincipal, DeerfieldCEO, Drop GenieCEO, Dualogics LLCManaging Director, EGB VenturesDirector, Eikonizo TherapeuticsCEO, Eikonizo TherapeuticsCEO, Elsius BiomedicalOwner, enERGetics BiopharmaceuticalChief Operating and Chief Business Officer, EpimAb Biotherapeutics Inc.CEO, ethris GmbHDirector of Business Development, North America, EuretosSenior Director, Business Development, EvotecDirector BD, Fortress BiotechDirector of Business Development, FreeMind GroupPartner, Freshfields Bruckhaus DeringerPartner, Freshfields Bruckhaus DeringerCounsel, Freshfields Bruckhaus DeringerPartner, Freshfields Bruckhaus DeringerDirector, FTI ConsultingSenior Managing Director, FTI Consulting, IncManaging Director, GE VenturesManaging Director, Goldman SachsHead of Global Healthcare, Goldman SachsHead of Healthcare Banking EMEA, Goldman Sachs





Executive Vice President & Chief Busines Officer Corporate Strategy and Business Development, H. LundbeckCOO, Haima Therapeutics LLCPartner, HealthCare Royalty PartnersCEO, HemoGenyx Pharmaceuticals plcManaging Director of Life Sciences, Hercules CapitalCEO, HoloBiomeManaging Director, Horizon Technology FinanceCTO, IBMExecutive Vice President Chief Business Officer, ImmunSYS Inc.Chief Financial Officer, ImmunSYS, Inc.CEO & President, Inanovate IncEVP Medicines Access, Inceptua GroupVP Consulting, Inceptua Medicines AccessEditor, InnoHealthCFO, Insightra MedicalChairman & CEO, Inspirata, Inc.CEO, Intrommune TherapeuticsCo-Founder & CSO, Intrommune TherapeuticsSVP, Global BD & Alliance Management, IpsenManaging Director, Ipsen VenturesMarketing, IQVIAUS Tech Solutions, National Emerging BioPharma Strategy Lead and Mid-Atlantic Regional GM, IQVIADirector, Emerging Biopharma Solutions, IQVIASenior Director, IQVIAInnovation Vice President, Design & Delivery, IQVIAEVP and Chief Customer Officer, IQVIASr Principal and Segment Lead, IQVIAAlliance Manager, IQVIAVP & GM Strategy and Portfolio Planning, IQVIAR&D Solutions Business Development, IQVIADirector, Account Management, IQVIACTO, Javelin BiotechCEO, Javelin BiotechInvestment Professional, JDRF T1D FundExternal Innovation Search and Evaluation, Eastern United States, Johnson & JohnsonChairman & General Partner, Julz Co LLCDirector, Julz Co LLCCFO, Karuna TherapeuticsFounder, kronos.vcCEO, Lansdowne LabsPresident & CEO, LaVoieHealthScienceAVP, Investor Relations and Corporate Communications, LaVoieHealthScienceSVP, IR & Business Development, LaVoieHealthScienceHead of Investments, Longevity Vision Fund

Venture Partner, Longevity Vision FundPresident & CEO, Luminary TherapeuticsVP Business Development, Luminary TherapeuticsVice President & General Manager, LuxMed Systems, Inc.CEO, LuxMed Systems, Inc.Founder, Maidstone Life SciencesCFO, Massachusetts Life Sciences CenterAssociate Director Business Development, Massachusetts Life Sciences CenterVP Marketing & Communications, Massachusetts Life Sciences CenterVP of Industry Programs & Relations, Massachusetts Life Sciences CenterDirector of Business Development, Massachusetts Life Sciences CenterPresident & CEO, MedWaves, Inc.Associate Vice President and Head of Boston Innovation Hub, BD&L, MerckSVP & Global Head of Business Development & Alliance Management, Merck KGaACFO, Minovia TherapeuticsVP Chemistry, MitobridgeHead, Regulatory Affairs, Moderna TherapeuticsCOO, Morgan PrestwichPartner, Morrison & Foerster LLPPartner, Morrison FoersterCEO, Mount Tam BiotechnologiesPrincipal, MP Healthcare Venture ManageManaging Director, MPM CapitalPartner, MRL Venture FundPartner, MVM Life Science Partners LLPCEO, MycoviaSVP, Commercialization, Mycovia Pharmaceuticals, Inc.CEO, NDA GroupDirector, Business Development, NDA GroupCSO, NDA GroupCEO, NeuroHealing Pharmaceuticals, Inc.CEO, retired, North Shore InnoVenturesHead of BD&L, NovartisPrincipal, Novartis Venture FundsFounder & CEO, Oncologie, IncCDO, Oncologie, IncCEO & Co-Founder, Oscine TherapeuticsCEO, Panorama MedicineVP of Clinical Operations, Parsley HealthPartner, Partners HealthcarePresident, PBM CapitalDirector, PersComm Ltd.President & CEO, Personal Remedies LLCSVP Worldwide Business Development, Pfizer





VP, Head of R&D, PIC TherapeuticsCEO, PIC TherapeuticsBiology Professional, PIC TherapeuticsPartner, Pillar VCPartner, Polaris PartnersCEO, PurpleSunManaging Director, RA Capital ManagementCEO & Director, Real EndpointsVP & Head of Business Development, Regeneron Pharmaceuticals IncCEO, Repair BiotechnologiesPrincipal Scientist, Repair BiotechnologiesCEO, Resolute.aiCTO, Resolute.AiCEO, Rinri TherapeuticsCEO, President, Co-Founder, Riparian PharmaCFO, Rodin TherapeuticsPresident & CEO, Rodin Therapeutics IncHead of M&A, SanofiEVP, Strategy & Business Development, SanofiCEO, SciBac Inc.Founder, Sen-Jam PharmaceuticalCEO, Sen-Jam PharmaceuticalsPresident & CEO, Siamab TherapeuticsCBO, SigilonPresident & Chief Executive Officer, Sigilon TherapeuticsDirector of Business Development, Sigilon TherapeuticsCEO, Siglion TherapeuticsVP of Clinical Services, Simple HealthInvestor, Sky VenturesPresident, CEO & Director, SojournixCTO, Solid BioCEO, Solid Biosciences IncCFO, Sorrento Therapeutics IncCEO, Spring Bank Pharmaceuticals IncFounder & Managing Director, Springhood Ventures LLCProduct & Business officer, sRNAlyticsCEO, Stoke Therapeutics IncSenior Director, Clinical Development, Sunovion Pharmaceuticals Inc.Operating Partner, Sweetwater Capital PartnersCo Founder, Chairman of the Board, President & Chief Executive Officer, SynDevRxCo-Founder & VP of Business Development, SynDevRxSVP, Head of Discovery Services, SyngeneHead of Marketing, Syngene InternationalBusiness development, Syngene internationalLead- Discovery Services, Syngene International

CCO, Syngene International LtdCEO, Tactical TherapeuticsGlobal Business Development Officer, Takeda Pharmaceutical CompanyPresident & CEO, Therapeutic Vision IncCEO & Co-Founder, TiaCBO & Co-Founder, Totient Inc.Partner, TransPacific Venture Capital PartnersCEO, Tuned TherapeuticsDirector, Advanced Technology, VSP GlobalPartner, Wilson Sonsini Goodrich & RosatiPartner, Wilson Sonsini Goodrich & RosatiPartner, Wilson Sonsini Goodrich & RosatiCEO, Windgap Medical, Inc.Co-Founder, President & CEO, X-Biotix Therapeutics IncExecutive Advisor of Business Development, X-ChemFellow, Yale


Delegate packages


Register online at www.lsxleaders.com/usa

If you have any questions please contact: [email protected], +44 (0) 203 637 5908


Corporate Standard 1-day Ticket*

• Access to early partnering 7th Oct• Access to 1 of 3 suitable CEO Forums 7th Oct

(life science CEOs only)• Access to drinks reception 7th Oct• Access CEO VIP dinner 7th Oct

OR

• Access to conference day 8th Oct• Access to conference workshops 8th Oct• Access to 1-2-1 partnering portal• Access to drinks reception 8th Oct

Until 19 July 19 - $795 / $595Until 09 Aug 19 - $895 / $695Until 30 Aug 19 - $995 / $795

Until 20 Sept 19 - $1,195 / $995Full Price - $1,395 / $1,195

* Biotech / Medtech / Healthtech / Pharma / Big

Tech company executives only

Services 1-day Ticket***

• Access to conference day 8th Oct• Access to 1-2-1 partnering portal• Access to drinks reception 8th Oct

Corporate VIP 2-day Ticket*

• Access to early partnering 7th Oct• Access to 1 of 3 suitable CEO Forums 7th Oct (life

science CEOs only)• Access to drinks reception 7th Oct• Access CEO VIP dinner 7th Oct• Access to conference day 8th Oct• Access to conference workshops 8th Oct• Access to 1-2-1 partnering portal• Access to drinks reception 8th Oct

Until 19 July 19 - $1,345Until 09 Aug 19 - $1,495Until 30 Aug 19 - $1,645Until 20 Sept 19 - $1,795

Full Price - $1,945

* Biotech / Medtech / Healthtech / Pharma / Big Tech company executives only

Until 19 July 19 - $895Until 09 Aug 19 - $995Until 30 Aug 19 - $1,145Until 20 Sept 19 - $1,295

Full Price - $1,445

*** Financial / Professional / Contract Services

Investor VIP 2-day Ticket**

• Access to early partnering 7th Oct• Access to Investor Forum 7th Oct• Access to drinks reception 7th Oct• Access Investor VIP dinner 7th Oct• Access to conference day 8th Oct• Access to conference workshops 8th Oct • Access to 1-2-1 partnering portal• Access to Investor VIP lounge• Access to drinks reception 8th Oct

Until 19 July 19 - $345Until 09 Aug 19 - $395Until 30 Aug 19 - $445Until 20 Sept 19 - $495

Full Price - $595

** Qualified investors only



mailto:[email protected]

Industry Leading Events for the Life Science C-Suite


Contact us today to find out how to get involved in any or all of our events. www.lsxleaders.com/events

2-3 September 2020Nasdaq Offices, Stockholm, Sweden www.lsxleaders.com/nordic

7-8 October 2019Convene Convention Center, Boston, USA www.lsxleaders.com/usa

13-14 November 2019The Crystal, Royal Victoria Dock, London, UK www.lsxleaders.com/digihealth

19 November 2019The Hilton Waldorf, London, UK www.lsxleaders.com/investival

19 November 2019The Honourable Artillery Company, London, UK www.lsxleaders.com/lifestars

4-5 February 2020etc. venues, 133 Houndsditch, London, UK www.lsxleaders.com/london

21-22 April 2020 etc. venues, 133 Houndsditch, London, UK www.longevityleaders.com

http://www.lsxleaders.com/events

Conference Floorplan


Onsite Team

Terry O’DwyerCo-CEO

Josh Dance SVP, Production

Brooke RobertsHead of VIP Networking (1:1 Meetings)

Rebecca Herne Head of Operations (Registration)

Neil Darkes Co-CEO

Matthew Pullan SVP, BD



Created by

Contact Us

www.lsxleaders.com/usa #lsxusa @lsxleaders

For speaker opportunities contact:

Josh Dance, [email protected] +44 (0) 203 637 5908

For sponsor opportunities contact:

Matt Pullan, SVP, BD & [email protected]+44 (0) 203 637 5908 For bookings contact:

Joseph Knight, BD [email protected] +44 (0) 203 637 5908

Or visit us at www.lsxleaders.com/usa

http://www.lsxleaders.com/lsx-usa-congress

mailto:josh%40lsxleaders.com?subject=

mailto:matt%40lsxleaders.com%20?subject=

mailto:joe%40lsxleaders.com?subject=


strategy, investment, partnering and deal ... 2019 brochure.pdf17:30 - general macro challenge...

Documents